New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
08:06 EDTBDXBecton Dickinson receives FDA clearance to market BD MAX StaphSR assay
BD Diagnostics, a segment of Becton Dickinson, announced it has received FDA clearance to market the BD MAX StaphSR Assay for use on the fully-automated BD MAX System. The assay, with eXTended Detection Technology, detects Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs, including mecA dropout mutants and new strains of MRSA that may not be detected by other assays.
News For BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
15:46 EDTBDXRetractable Technologies reports recognition of payment from Becton, Dickinson
Retractable Technologies (RVP) reports that in the second quarter, RTI will record as income and remove from RTIís current liabilities, the $7,724,826 judgment amount previously paid by Becton, Dickinson and Company (BDX) for damages awarded as a result of BDís infringement of RTIís patents. This patent infringement case and related appeals have concluded. The patent claims were severed from RTIís other claims against BD in 2008. The other portion of the case in which the District Court granted RTI a final judgment for $352M plus other relief is not directly affected by the conclusion of the patent case and the related recognition of the judgment amount.
May 13, 2015
08:07 EDTBDXBecton Dickinson receives FDA clearance for insulin infusion set
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use